What is Lo Loestrin® Fe?
Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy. If you are moderately obese, discuss with your healthcare provider whether Lo Loestrin Fe is the best choice for you.
IMPORTANT RISK INFORMATION
WARNING TO WOMEN WHO SMOKE
Do not use Lo Loestrin Fe if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots, or stroke. This risk increases with age and the number of cigarettes you smoke.
Who should not take Lo Loestrin Fe?
Do not use Lo Loestrin Fe if you have kidney, liver, or adrenal disease because this could cause serious heart and health problems, or if you have or have had blood clots, history of heart attack or stroke, high blood pressure that medicine cannot control, breast cancer or any cancer that is sensitive to female hormones, liver disease or liver tumors, unexplained bleeding from the vagina, or if you are or may be pregnant.
What else should I know about taking Lo Loestrin Fe?
Treatment with Lo Loestrin Fe should be stopped if you have a blood clot, and at least 4 weeks before and through 2 weeks after major surgery. You should not take Lo Loestrin Fe any earlier than 4 weeks after having a baby or if you are breastfeeding. If you experience yellowing of the skin or eyes due to problems with your liver, you should stop taking Lo Loestrin Fe. If you are pre-diabetic or diabetic, your doctor should monitor you while using Lo Loestrin Fe and should evaluate you if you have any significant change in headaches or irregular menstrual bleeding.
What are the most serious risks of taking Lo Loestrin Fe?
Lo Loestrin Fe increases the risk of serious conditions including blood clots, stroke, and heart attack. These can be life-threatening or lead to permanent disability.
What are the possible side effects of Lo Loestrin Fe?
The most common side effects reported by women taking Lo Loestrin Fe in a study were nausea/vomiting, headache, spotting or bleeding between menstrual periods, painful menstruation, weight change, breast tenderness, acne, abdominal pain, anxiety, and depression.
Birth control pills do not protect you against any sexually transmitted disease, including HIV, the virus that causes AIDS.
Please see the Patient Information LeafletPatient Information Leaflet for Lo Loestrin Fe, including Boxed Warning, available at www.loloestrin.com.
*This offer is valid only for patients with commercial prescription drug insurance and applies to prescriptions for Lo Loestrin Fe. Most eligible insured patients will pay no more than $25 per 28-day supply for each of up to 12 prescription fills. Other eligible insured patients should check with their pharmacist for their copay discount. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. Please see full terms and conditions at actavissavings.com.
1. Lo Loestrin® Fe prescribing information. Rockaway, NJ: Warner Chilcott (US), LLC; 2012. 2. Data on file. Rockaway, NJ: Warner Chilcott (US), LLC. 3. Sech L, Segall-Gutierrez P, Silverstein E, et al. Oral contraceptives. The Merck Manual Web site. http://www.merckmanuals.com/professional/gynecology_and_obstetrics/family_planning/oral_contraceptives.html#v8579722. Updated August 2013. Accessed January 29, 2014. 4. Oral contraceptive survey. Harris Poll. July 2014. 5. Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception. 2004;70(5):371-377. 6. Birth control patient education pamphlet. Washington, DC: The American College of Obstetricians and Gynecologists; November 2013. 7. Menstruation and the menstrual cycle. Womenshealth.gov Web site. https://www.womenshealth.gov/publications/our-publications/fact-sheet/menstruation.html. Updated October 21, 2009. Accessed March 27, 2014. 8. Hatcher RA, Trussell J, Stewart F, et al. Contraceptive Technology. 18th ed. New York, NY: Ardent Media; 2004.